Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Joon Oh Park, Baek Yeol Ryoo, Chia Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Takuji Okusaka, L. Bowman, Zhanglin Lin Cui, Allicia C. Girvan, Paolo B. Abada, Ling YangAndrew X. Zhu

Research output: Contribution to journalComment/debate

4 Citations (Scopus)

Abstract

The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)135-136
Number of pages2
JournalEuropean Journal of Cancer
Volume100
DOIs
Publication statusPublished - 2018 Sep

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))'. Together they form a unique fingerprint.

  • Cite this

    Chau, I., Peck-Radosavljevic, M., Borg, C., Malfertheiner, P., Seitz, J. F., Park, J. O., Ryoo, B. Y., Yen, C. J., Kudo, M., Poon, R., Pastorelli, D., Blanc, J. F., Chung, H. C., Baron, A. D., Okusaka, T., Bowman, L., Cui, Z. L., Girvan, A. C., Abada, P. B., ... Zhu, A. X. (2018). Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). European Journal of Cancer, 100, 135-136. https://doi.org/10.1016/j.ejca.2018.06.002